Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Three-Compartment Open Model01:06

Three-Compartment Open Model

The three-compartment open model is a pharmacokinetic model used to describe the distribution and elimination of drugs following extravascular administration. It comprises a central compartment representing the plasma and two peripheral compartments. The highly perfused peripheral compartment represents organs and tissues with a rich blood supply, such as the liver, kidneys, and lungs. The scarcely perfused peripheral compartment represents tissues with lower blood supply, such as adipose...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An exploratory, qualitative study of treatment preferences among participants in a TB therapeutic trial.

IJTLD open·2026
Same author

Rifampicin-resistant TB in paediatrics: a patient series from a secondary health facility in Northern Malawi.

Public health action·2026
Same author

Response to the Union's statement on ongoing conflicts and impact on health services.

IJTLD open·2026
Same author

Yield of a contact investigation among children living with drug-resistant TB patients.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

The time is now: making the case for compassionate use/pre-approval access to new TB drugs.

IJTLD open·2025
Same author

Clinical best practices for caring for people with expanded resistance to newer TB drugs.

IJTLD open·2025

Related Experiment Video

Updated: Jun 1, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

Programmatic management of multidrug-resistant tuberculosis: models from three countries.

J Furin1, J Bayona, M Becerra

  • 1Department of Social Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. jjf38@case.edu

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
|June 15, 2011
PubMed
Summary

Implementing multidrug-resistant tuberculosis (MDR-TB) treatment requires addressing six key areas for successful programmatic expansion. These include baseline assessments, collaboration, cost minimization, and targeted support.

More Related Videos

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray
07:35

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray

Published on: April 25, 2014

Related Experiment Videos

Last Updated: Jun 1, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray
07:35

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray

Published on: April 25, 2014

Area of Science:

  • Public Health
  • Infectious Disease Management
  • Global Health Security

Background:

  • Multidrug-resistant tuberculosis (MDR-TB) presents a significant global health challenge.
  • A critical gap exists in the effective programmatic implementation of MDR-TB treatment strategies worldwide.

Purpose of the Study:

  • To describe and analyze multidrug-resistant tuberculosis (MDR-TB) treatment models.
  • To identify common themes and critical factors for successful MDR-TB program development and implementation across diverse settings.

Main Methods:

  • Qualitative data analysis over a 13-year period.
  • Programmatic analysis of MDR-TB treatment in Peru, Russia, and Lesotho.
  • Pattern analysis to identify overarching themes in treatment models.

Main Results:

  • Six common themes emerged across all three country programs: baseline assessments, collaborator identification, locus of care, minimizing patient costs, targeted interventions for vulnerable populations, and technical assistance/funding.
  • Analysis of site-specific commonalities and differences within these themes.
  • Detailed program evolution from initial implementation to maturity.

Conclusions:

  • All multidrug-resistant tuberculosis (MDR-TB) treatment programs should integrate these six identified areas into their development and implementation strategies.
  • Addressing these themes can improve the effectiveness and reach of MDR-TB care globally.